As of June 30, 2026, Kintor Pharmaceutical Ltd carries a market capitalization of 933.80M, placing it among publicly traded companies globally. Its enterprise value stands at 1.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 933.80M |
| Enterprise Value | 1.05B |
Kintor Pharmaceutical Ltd's next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
As of June 30, 2026, Kintor Pharmaceutical Ltd has 488.90M shares outstanding.
| Shares Outstanding | 488.90M |
These figures are as of June 30, 2026.
| PB Ratio | 7.40 |
| P/TBV Ratio | 60.01 |
As of June 30, 2026, Kintor Pharmaceutical Ltd maintains a current ratio of 0.26, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.26 |
| Quick Ratio | 0.17 |
| Debt / Equity | 122.30 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 123.00 |
As of the close on November 17, 2026, Kintor Pharmaceutical Ltd's stock has declined approximately 32.87% over the past 52 weeks. The 50-day moving average sits at 1.64, while the 200-day moving average is 2.25.
| 52-Week Price Change | -32.87% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 2.25 |
As of June 30, 2026, Kintor Pharmaceutical Ltd holds 36.17M in cash and equivalents against 154.39M in total debt, resulting in a net debt position of 117.43M. Total book value stands at 126.24M, with working capital of -155.60M providing operational flexibility.
| Cash & Cash Equivalents | 36.17M |
| Total Debt | 154.39M |
| Net Debt | 117.43M |
| Equity (Book Value) | 126.24M |
| Book Value Per Share | 0.26 |
| Working Capital | -155.60M |
Already premium?